Intervention

ALT-801

ClinicalTrials.gov intervention label

Clinical trials6

Recruiting0

Common conditions6

Lead sponsors shown2

Clinical trials

6 shown

Efficacy and Safety of ALT-801 in the Treatment of ObesityNCT05295875 · 2022-03-31

Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)NCT05292911 · 2022-03-09

ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)NCT05134662 · 2022-02-01

ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)NCT05006885 · 2021-09-30

ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and TolerabilityNCT04561245 · 2020-11-10

Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic MalignanciesNCT00496860 · 2007-05-01

Common conditions

Non-Alcoholic Fatty Liver Disease2 Nonalcoholic Steatohepatitis1 Obesity1 Obesity/Overweight1 Progressive Metastatic Malignancies1 Type 2 Diabetes1

Leading sponsors

Altimmune, Inc.5 Altor BioScience1

Trial status mix

COMPLETED6

Phase mix

PHASE15

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.